antibody staining is a simple technique for assessing the proliferation fraction than can be performed on a small amount of tissue taken at routine biopsy without prior injection of thymidine analogues.
Proliferation in human tumour cells has been previously difficult to measure, but there is evidence that it may be clinically important. Clinically, bladder tumours can grow quite rapidly, volume doubling times being estimated to have a mean value of about 70 days (Steel, 1977) , and relapse when it does occur develops early. Measurement of proliferation in a series of 350 patients with bladder carcinoma using flow cytometric analysis of S-phase fraction demonstrated that high S-phase fraction carries a poor prognosis (Tribukait et al., 1986) . However, apart from technical difficulties in preparing suitable single tumour cell suspensions, when a tumour is aneuploid, the determination of the percentage of the cells in S-phase becomes less precise and sometimes impossible. Therefore, an alternative method of measuring proliferation is needed.
Ki-67 is a murine monoclonal antibody raised against the human Hodgkin's disease-derived cell line L428, and found to react with a nuclear antigen expressed in proliferating cells (Gerdes et al., 1983) . The nature of the antigen has not been characterised, but it has been suggested that Ki-67 recognises a nuclear protein forming part of the DNA replicase complex (Loke et al., 1987) , and has been localised to the nucleolar cortex and the periphery of metaphase chromosomes (Verheijen et al., 1989a and b) . A wide range of Ki-67 indices (the number of Ki-67 positive tumour cells divided by the total number of tumour cells %) have been reported from a range of human tumours, the largest range being in Non-Hodgkin's Lymphoma range 0.5-100% (Hall et al., 1988) . The Ki-67 index appears to be related to the biological aggressiveness of several tumours. This has been demonstrated in NonHodgkin's Lymphoma, lung carcinomas and breast carcinoma (Schrape et al., 1987; Gatter et al., 1986; , the more aggressive tumours having the higher indices. At least two reports have suggested that the Ki-67 index, although a static measure, may provide a guide to the proliferation rate of tumours (Hall et al., 1988; Price et al., 1989 Grading by histological examination Histological examinations of 6 gm cryostat sections stained with haematoxylin and eosin were made by one observer (J.N.). The biopsies were assessed to ensure that adequate amounts of well-preserved tumour was present for cell counting and that the portion of frozen tissue was representative of the tumour as a whole.
A histological grade was assigned to each tumour using the grading system proposed by Ash (1940) and based on the tumour's growth pattern, cytological appearance including cellular atypia and nuclear pleomorphism, and number of mitotic figures. Histological grading was performed without prior knowledge of the clinical stage or Ki-67 proliferation index of the tumours.
Given that the differentiation of tumours may vary from area to area (Jewett, 1946 ) the histological appearance of the cryostat sections was compared with sections of the formalinfixed paraffin-embedded tumour so that any non-representative frozen biopsies could be identified.
Immunohistochemistry 6 tm cryostat sections were immunohistochemically labelled with the monoclonal antibody Ki-67 (Dako Ltd.) using an indirect immunoperoxidase method. Following a 10 min fixation in acetone, slides were incubated with Ki-67 at a dilution of 1:10 for 30 min. After a phosphate-buffered saline (PBS) wash, sections were incubated with peroxidaseconjugated rabbit anti-mouse immunoglobulins (Dako Ltd.) at a dilution of 1:20 for 30 min. Following a further PBS wash, the brown peroxidase stain was visualised using the chromogenic -substrate diaminobenzidine. Sections were then counterstained with haematoxylin before mounting. Negative controls substituted Ki-67 antibody with PBS. Positive controls used were cytocentrifuge preparations of a human tumour cell line, H x 151, derived from a cervix tumour (Kelland et al., 1987) . All incubations were carried out at room temperature in a humidified atmosphere. Clinical data and statistical analysis Clinical follow-up was available in all patients (range months, mean 8.5 months).
The Mann-Whitney non-parametric test was used to compare pairs of groups of patients, and the relationship between the Ki-67 index and histological grade and stage was evaluated using the Spearman rank correlation. 
Results
Immunohistochemical labelling with Figure 2 shows the typical appearance of a bladder carcinoma immunostained with Ki-67 demonstrating the positive labelling of tumour cell nuclei. The distribution of positive nuclei varied from specimen to specimen but in the majority of samples they were diffusely scattered throughout the section. Intrasection variation on active searching was always less than 15%. Intrasample variation was always less than 4%. Cytoplasmic labelling resistant to the blocking of endogenous peroxidase was rarely seen, but where present was weak and did not interfere with the identification of positive nuclei. In 5/69 (7.2%) specimens, taken from tumours of various grades and stages, repeatedly showed no labelling with the Ki-67 antibody. This remains unexplained and these patients were excluded from analysis. A Ki-67 index was derived in 64 samples from 59 patients. Ki-67 index ranged from 3.0-65.8% (median 25.3%). In 19 samples (29.7%), sections were cut from either two or three levels of the biopsy, the variation in Ki-67 index had a mean value of 3.7 ± 0.5% (range 0.2-10%). In 100% of cases the histological review of cryostat sections and formalin-fixed paraffin embedded sections suggested that the derived Ki-67 index was representative of the biopsy. In three cases (5.1%), more than one sample was available from the same tumour and in these cases, Ki-67 index varied by no more than 8%.
Correlation of index with known prognostic factors Ki-67 index was correlated with known prognostic factors. There was a highly significant positive correlation between Ki-67 index and both T stage (rs = 0.44, P = 0.002) and histological grade (rs = 0.60, P <0.001). See Figures 3 and 4 . Patients with invasive disease (T2, T3, T4) had higher Ki-67 indices, (median 26.3%, range 9.6-65.8%) than those with disease confined to the bladder (Tis, Ta, Tl), (median 12.5%, range 3-60.1%) P<0.001 (Mann-Whitney).
Nodal disease was found in four patients (6.8%), and these patients had higher Ki-67 indices than those patients with disease confined to the bladder, although this difference did not reach significance (P = 0.08).
Distant metastatic disease was present at diagnosis in 4/59 (7%) of patients, all of whom had invasive bladder disease.
In all four patients the Ki-67 index was > 29%, although this was not significantly higher than in those without metastatic disease (P = 0.21). One patient has developed metastatic disease 15 months after diagnosis and the Ki-67 index of the original biopsy was the highest recorded (65.8%).
Forty-three specimens were obtained from 40 patients who presented with non-invasive disease, of which 24 (5.6%) were recurrences. There was no difference in the Ki-67 index between the primary and recurrent specimens. No correlation was found between Ki-67 index and size, site, and number of tumours, duration of symptoms, time to local recurrence or age and sex of the patient.
Discussion
Ki-67 immunostaining is a simple technique for assessing proliferation that can be performed on a small amount of tissue taken at routine biopsy without injection of thymidine analogues. Derivation of Ki-67 index was straightforward, and counting of large number of nuclei reduced sampling error.
Ki-67 has been shown to bind to cells in active proliferation and is thought to stain cells in S phase, G2 and most of GI cells (Gerdes et al., 1983 (Gerdes et al., , 1984 . The range of immunohistochemically derived Ki-67 index derived from the bladder tumours (3.0-65.8%) is similar to the range in other human tumours, e.g. breast carcinomas (Barnard et al., 1987) . As Ki-67 immunoreactivity is only detectable on frozen tissue, without extended follow-up, its clinical importance can only be inferred from correlation with known prognostic factors. In bladder carcinoma the Ki-67 index would appear to be related to the biological aggressiveness of the tumour as measured by TNM stage and histological grade. This is similar to the findings in Non-Hodgkin's Lymphoma, lung and breast carcinoma (Hall et al., 1988; Gatter et al., 1986; Barnard et al., 1987) .
The relationship between proliferative activity and biological aggressiveness can be explained by two hypotheses. Firstly, that metastatic potential relies on the acquisition of specific genetic abnormalities which are acquired randomly (McMillan & Hart, 1987) and are thus more likely to occur after repeated cell divisions in a rapidly growing tumour (Ling et al., 1984) . Secondly, that the degree to which a tumour cell escapes from its regulatory control, is also reflected in the way in which it escapes from its normal proliferative control (Tubiana & Courdi, 1989) .
If the Ki-67 index of primary bladder carcinoma indicates those biologically more aggressive tumours, it may be used to select patients with non-invasive disease who require more frequent follow-up, or those patients with invasive disease who are destined to develop metastatic disease and who may benefit from adjuvant chemotherapy.
Furthermore, there is evidence that the Ki-67 index provides information about the proliferation rate of human tumours (Hall et al., 1988; Price et al., 1989) . If the Ki-67 index identifies those tumours with a higher per cent of cells in cycle, it may provide a useful proliferation marker for stratification in radiotherapy trials where subsets of tumours able to repopulate rapidly during conventional treatment may benefit from accelerated fractionation. This question is at present being addressed in a prospective clinical trial.
